NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ:SMLR). Investors who purchased Semler securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SMLR.

SAN FRANCISCO, CA / ACCESS Newswire / June 5, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NANO Nuclear Energy Inc. ("NNE" or "the Company") (NASDAQ:NNE). Investors who purchased NNE securities prior to May 8, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NNE.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FMC Corporation ("FMC" or "the Company") (NYSE:FMC). Investors who purchased FMC securities prior to November 16, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FMC.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atkore Inc. ("Atkore" or "the Company") (NYSE:ATKR). Investors who purchased Atkore securities prior to August 2, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATKR.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Manhattan Associates, Inc. ("Manhattan Associates" or "the Company") (NASDAQ:MANH). Investors who purchased Manhattan Associates securities prior to October 22, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MANH.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Grocery Outlet Holding Corp. ("Grocery Outlet" or "the Company") (NASDAQ:GO). Investors who purchased Grocery Outlet securities prior to April 9, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GO.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integral Ad Science Holding Corp. ("IAS" or "the Company") (NASDAQ:IAS). Investors who purchased IAS securities prior to March 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IAS.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Is now a good time for traders and advisors to consider amplifying their real estate exposure? There are a few crucial factors that may support doing so.

Despite the tariff volatility, uranium has been a proverbial rock among the crashing waves. The metal has been exhibiting resilience amid renewed interest from investors backed by solid fundamentals.

Forecasts of a recession are looming among market experts. Making sense of recession probabilities can be complex.

I maintain a Buy rating on the stock due to strong revenue growth and expanding profit margins. The company's leadership in its sector and robust product pipeline support long-term earnings potential. Recent quarterly results exceeded expectations, highlighting effective cost controls and resilient demand.

OMAH offers Berkshire Hathaway-focused equity exposure with a 15% targeted annual distribution, achieved via an active options-writing strategy. The fund appeals to income-seeking investors by providing monthly payouts, despite Berkshire itself not paying dividends. The distribution target raises sustainability concerns for those wanting capital preservation, with regard to the possibility of NAV erosion over time.

EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.

AFRM rises above its 200-day SMA as product growth, loyal users and global expansion boost investor interest.

The median call among 17 banks and investment groups is for the index to end the year at 5950 points, 0.3% lower than Wednesday's closing level.

Ahead of its Worldwide Developer Conference on June 9, Apple on Thursday offered a new update on its global App Store business, sharing that developers generated $1.3 trillion in billings and sales in 2024. The company stressed that 90% of those billings and sales did not involve paying Apple a commission.